MiR-150-5p and Let-7b-5p in Blood Myeloid Extracellular Vesicles Track Cognitive Symptoms in Patients with Multiple Sclerosis

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2022 May 14

PMID 35563859

Authors

Federica Scaroni

Caterina Visconte

Maria Serpente

Maria Teresa Golia

Martina Gabrielli

Marijn Huiskamp

Hanneke E Hulst

Tiziana Carandini

Milena De Riz

Anna Pietroboni

Emanuela Rotondo

Elio Scarpini

Daniela Galimberti

Charlotte E Teunissen

Maureen van Dam

Brigit A de Jong

Chiara Fenoglio

Claudia Verderio

Affiliations

Soon will be listed here.

Abstract

Cognitive deficits strongly affect the quality of life of patients with multiple sclerosis (MS). However, no cognitive MS biomarkers are currently available. Extracellular vesicles (EVs) contain markers of parental cells and are able to pass from the brain into blood, representing a source of disease biomarkers. The aim of this study was to investigate whether small non-coding microRNAs (miRNAs) targeting synaptic genes and packaged in plasma EVs may reflect cognitive deficits in MS patients. Total EVs were precipitated by Exoquick from the plasma of twenty-six cognitively preserved (CP) and twenty-three cognitively impaired (CI) MS patients belonging to two independent cohorts. Myeloid EVs were extracted by affinity capture from total EVs using Isolectin B4 (IB4). Fourteen miRNAs targeting synaptic genes were selected and measured by RT-PCR in both total and myeloid EVs. Myeloid EVs from CI patients expressed higher levels of miR-150-5p and lower levels of let-7b-5p compared to CP patients. Stratification for progressive MS (PMS) and relapsing-remitting MS (RRMS) and correlation with clinical parameters suggested that these alterations might be attributable to cognitive deficits rather than disease progression. This study identifies miR-150-5p and let-7b-5p packaged in blood myeloid EVs as possible biomarkers for cognitive deficits in MS.

Citing Articles

Approaches and Challenges in Characterizing the Molecular Content of Extracellular Vesicles for Biomarker Discovery.

Kumari S, Lausted C, Scherler K, Ng A, Lu Y, Lee I Biomolecules. 2025; 14(12.

PMID: 39766306 PMC: 11674167. DOI: 10.3390/biom14121599.

A Literature Review and Meta-Analysis on the Potential Use of miR-150 as a Novel Biomarker in the Detection and Progression of Multiple Sclerosis.

Arcas V, Fratila A, Moga D, Roman-Filip I, Arcas A, Roman-Filip C J Pers Med. 2024; 14(8).

PMID: 39202006 PMC: 11355600. DOI: 10.3390/jpm14080815.

Extracellular Vesicles: The Next Generation of Biomarkers and Treatment for Central Nervous System Diseases.

Zanirati G, Dos Santos P, Alcara A, Bruzzo F, Ghilardi I, Wietholter V Int J Mol Sci. 2024; 25(13).

PMID: 39000479 PMC: 11242541. DOI: 10.3390/ijms25137371.

CNS cell-derived exosome signatures as blood-based biomarkers of neurodegenerative diseases.

Park C, Weerakkody J, Schneider R, Miao S, Pitt D Front Neurosci. 2024; 18:1426700.

PMID: 38966760 PMC: 11222337. DOI: 10.3389/fnins.2024.1426700.

Exploring miRNAs' Based Modeling Approach for Predicting PIRA in Multiple Sclerosis: A Comprehensive Analysis.

Gosetti di Sturmeck T, Malimpensa L, Ferrazzano G, Belvisi D, Leodori G, Lembo F Int J Mol Sci. 2024; 25(12).

PMID: 38928049 PMC: 11203572. DOI: 10.3390/ijms25126342.

References

Verderio C, Muzio L, Turola E, Bergami A, Novellino L, Ruffini F . Myeloid microvesicles are a marker and therapeutic target for neuroinflammation. Ann Neurol. 2012; 72(4):610-24. DOI: 10.1002/ana.23627. View

Vistbakka J, Sumelahti M, Lehtimaki T, Elovaara I, Hagman S . Evaluation of serum miR-191-5p, miR-24-3p, miR-128-3p, and miR-376c-3 in multiple sclerosis patients. Acta Neurol Scand. 2018; 138(2):130-136. DOI: 10.1111/ane.12921. View

Kurtzke J . Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983; 33(11):1444-52. DOI: 10.1212/wnl.33.11.1444. View

Martinez B, Peplow P . MicroRNAs as disease progression biomarkers and therapeutic targets in experimental autoimmune encephalomyelitis model of multiple sclerosis. Neural Regen Res. 2020; 15(10):1831-1837. PMC: 7513985. DOI: 10.4103/1673-5374.280307. View

Qian Y, Wu B, Lu Y, Zhou W, Wang S, Wang H . Novel PAK3 gene missense variant associated with two Chinese siblings with intellectual disability: a case report. BMC Med Genet. 2020; 21(1):31. PMC: 7017536. DOI: 10.1186/s12881-020-0957-x. View

Angerstein C, Hecker M, Paap B, Koczan D, Thamilarasan M, Thiesen H . Integration of MicroRNA databases to study MicroRNAs associated with multiple sclerosis. Mol Neurobiol. 2012; 45(3):520-35. DOI: 10.1007/s12035-012-8270-0. View

Benedict R, Amato M, DeLuca J, Geurts J . Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues. Lancet Neurol. 2020; 19(10):860-871. PMC: 10011205. DOI: 10.1016/S1474-4422(20)30277-5. View

Virgilio E, Vecchio D, Crespi I, Puricelli C, Barbero P, Galli G . Cerebrospinal fluid biomarkers and cognitive functions at multiple sclerosis diagnosis. J Neurol. 2022; 269(6):3249-3257. DOI: 10.1007/s00415-021-10945-4. View

Di Filippo M, De Iure A, Giampa C, Chiasserini D, Tozzi A, Orvietani P . Persistent activation of microglia and NADPH oxidase [corrected] drive hippocampal dysfunction in experimental multiple sclerosis. Sci Rep. 2016; 6:20926. PMC: 4757867. DOI: 10.1038/srep20926. View

10.

Zhao F, Cheng L, Shao Q, Chen Z, Lv X, Li J . Characterization of serum small extracellular vesicles and their small RNA contents across humans, rats, and mice. Sci Rep. 2020; 10(1):4197. PMC: 7060188. DOI: 10.1038/s41598-020-61098-9. View

11.

Schoonheim M, Popescu V, Rueda Lopes F, Wiebenga O, Vrenken H, Douw L . Subcortical atrophy and cognition: sex effects in multiple sclerosis. Neurology. 2012; 79(17):1754-61. DOI: 10.1212/WNL.0b013e3182703f46. View

12.

Fong J, Rae-Grant A, Huang D . Neurodegeneration and neuroprotective agents in multiple sclerosis. Recent Pat CNS Drug Discov. 2008; 3(3):153-65. DOI: 10.2174/157488908786242498. View

13.

Chaudhry A, Noor A, Degagne B, Baker K, Bok L, Brady A . Phenotypic spectrum associated with PTCHD1 deletions and truncating mutations includes intellectual disability and autism spectrum disorder. Clin Genet. 2014; 88(3):224-33. DOI: 10.1111/cge.12482. View

14.

Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland T . A Unique Microglia Type Associated with Restricting Development of Alzheimer's Disease. Cell. 2017; 169(7):1276-1290.e17. DOI: 10.1016/j.cell.2017.05.018. View

15.

Thebault S, Abdoli M, Fereshtehnejad S, Tessier D, Tabard-Cossa V, Freedman M . Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis. Sci Rep. 2020; 10(1):10381. PMC: 7316736. DOI: 10.1038/s41598-020-67504-6. View

16.

Geurts J, Barkhof F . Grey matter pathology in multiple sclerosis. Lancet Neurol. 2008; 7(9):841-51. DOI: 10.1016/S1474-4422(08)70191-1. View

17.

Hou B, Zhang Y, Liang P, He Y, Peng B, Liu W . Inhibition of the NLRP3-inflammasome prevents cognitive deficits in experimental autoimmune encephalomyelitis mice via the alteration of astrocyte phenotype. Cell Death Dis. 2020; 11(5):377. PMC: 7229224. DOI: 10.1038/s41419-020-2565-2. View

18.

Benedict R, Cookfair D, Gavett R, Gunther M, Munschauer F, Garg N . Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J Int Neuropsychol Soc. 2006; 12(4):549-58. DOI: 10.1017/s1355617706060723. View

19.

Youn Y, Shrestha S, Lee Y, Kim J, Lee J, Hur K . Neutrophil-derived trail is a proinflammatory subtype of neutrophil-derived extracellular vesicles. Theranostics. 2021; 11(6):2770-2787. PMC: 7806483. DOI: 10.7150/thno.51756. View

20.

Rong J, Xu L, Hu Y, Liu F, Yu Y, Guo H . Inhibition of let-7b-5p contributes to an anti-tumorigenic macrophage phenotype through the SOCS1/STAT pathway in prostate cancer. Cancer Cell Int. 2020; 20:470. PMC: 7526222. DOI: 10.1186/s12935-020-01563-7. View